John Willer, DO
Ophthalmology · The Dalles, ORNPI 1255383212
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,635 of the $4,173 with a category attached, or 63.1%. 20 manufacturers reported payments, led by Amgen at 39.6% of the total. Reporting peaked in 2022 at $1,702 and has fallen 85.6% since, to $245 in 2025.
Across 77 payments — averaging $54.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Merz North America, Inc.$365
- Bausch & Lomb, A Division Of Bausch Health US, LLC$328
- Regeneron Healthcare Solutions, Inc.$317
- Bausch & Lomb Americas Inc.$260
- Johnson & Johnson Surgical Vision, Inc.$258
- plus $993 from 14 others
What the payments were for
- Speaking & faculty fees$1,50036%
- Food & beverage$2,63563%
- Gifts$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 10 | $1,653 |
| Merz North America, Inc. | 3 | $365 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $328 |
| Regeneron Healthcare Solutions, Inc. | 10 | $317 |
| Bausch & Lomb Americas Inc. | 8 | $260 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $258 |
| Carl Zeiss Meditec USA, Inc. | 2 | $169 |
| Rayner Intraocular Lenses Limited | 1 | $153 |
| AbbVie(2 entities) | 8 | $149 |
| Harrow Eye, LLC | 1 | $125 |
| NEW World Medical,inc. | 6 | $98 |
| Sun Pharmaceutical Industries Inc. | 3 | $55 |
| Glaukos Corporation | 3 | $49 |
| Ivantis, Inc | 1 | $46 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Tarsus Pharmaceuticals, Inc. | 1 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Novartis | 1 | $18 |
| DUSA Pharmaceuticals, Inc. | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$1,500
- XEOMIN$231
- ASCLERA$231
- RAYNER CATARACT SET 1$153
- RayOne EMV$153
- RayOne Spheric$153
- RayOne Aspheric$153
- VYZULTA$125
- IHEEZO$125
- EYLEA$122
How this compares
$4,173 in reported general payments places this provider in the 85th percentile of 248 ophthalmology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 15 | $20,510 |
| LumiganBimatoprost | 19 | $9,729 |
| Cyclosporine | 15 | $8,609 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 31 | $6,870 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $6,410 |
| Latanoprost | 420 | $4,870 |
| Alphagan PBrimonidine Tartrate | 15 | $4,805 |
| Brimonidine Tartrate | 33 | $2,020 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 159 | $1,920 |
| Prednisolone Acetate | 39 | $1,868 |
| Travoprost | 14 | $1,825 |
| Timolol Maleate | 94 | $695 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 26 | $279 |
| Dorzolamide Hcl | 15 | $132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $149 | $41,45462 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 248 ophthalmology providers in Oregon.
Other ophthalmology in The Dalles
- David HuangCorvallis$67K
- Mark PennesiPortland$56K
- Rene ChoiPortland$21K
- Balamurali AmbatiEugene$19K
- Richard HoffmanEugene$17K
- Bart AdamsPendleton$17K
- Richard WeleberPortland$14K
- Aazim SiddiquiPortland$13K
- Kurt AndreasonBend$13K
- Poorav PatelMedford$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.